Evidens för trombosprofylax till medicinpatienter med hög risk
(2007) In Läkartidningen 104(20-21). p.1585-1587- Abstract
- Venous thromboembolism (VTE) is a common complication of hospitalization, and can result in substantial morbidity and treatment cost. In orthopedic and general surgery, it is common practice to use low-molecular-weight heparin as a thromboprophylaxis. For medical patients, however, the issue of prophylaxis remains under debate. Data from three recent large randomized studies of medical patients at risk for VTE: PREVENT, MEDENOX and ARTEMIS, were combined. They showed an absolute risk reduction (ARR) for symptomatic VTE of 0,48 percent, asymptomatic VTE of 2,5 percent with a subsequent increase in major bleedings of 0,38 percent. In most studies, low-molecular-weight heparin reduces the risk of VTE by approximately 45 percent. Thus, the... (More)
- Venous thromboembolism (VTE) is a common complication of hospitalization, and can result in substantial morbidity and treatment cost. In orthopedic and general surgery, it is common practice to use low-molecular-weight heparin as a thromboprophylaxis. For medical patients, however, the issue of prophylaxis remains under debate. Data from three recent large randomized studies of medical patients at risk for VTE: PREVENT, MEDENOX and ARTEMIS, were combined. They showed an absolute risk reduction (ARR) for symptomatic VTE of 0,48 percent, asymptomatic VTE of 2,5 percent with a subsequent increase in major bleedings of 0,38 percent. In most studies, low-molecular-weight heparin reduces the risk of VTE by approximately 45 percent. Thus, the prophylaxis may be efficient, but its clinical use is limited to patient populations with a high incidence of VTE. Further studies to identify medical patients who are at high risk and would benefit from prophylaxis are warranted. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1139956
- author
- Själander, Anders ; Jansson, Jan-Åke ; Bergqvist, David ; Eriksson, Henry and Svensson, Peter LU
- organization
- alternative title
- Evidence for thrombosis prophylaxis to high-risk patients
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Fibrinolytika, Ventrombos, Blodförtunningsmedel, Blodproppssjukdomar
- in
- Läkartidningen
- volume
- 104
- issue
- 20-21
- pages
- 1585 - 1587
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:17564265
- scopus:34249008480
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- b6c5e3fc-0155-438b-b4a2-480ec7062f78 (old id 1139956)
- alternative location
- http://ltarkiv.lakartidningen.se/artNo33449
- date added to LUP
- 2016-04-01 16:49:06
- date last changed
- 2022-01-28 22:23:09
@article{b6c5e3fc-0155-438b-b4a2-480ec7062f78, abstract = {{Venous thromboembolism (VTE) is a common complication of hospitalization, and can result in substantial morbidity and treatment cost. In orthopedic and general surgery, it is common practice to use low-molecular-weight heparin as a thromboprophylaxis. For medical patients, however, the issue of prophylaxis remains under debate. Data from three recent large randomized studies of medical patients at risk for VTE: PREVENT, MEDENOX and ARTEMIS, were combined. They showed an absolute risk reduction (ARR) for symptomatic VTE of 0,48 percent, asymptomatic VTE of 2,5 percent with a subsequent increase in major bleedings of 0,38 percent. In most studies, low-molecular-weight heparin reduces the risk of VTE by approximately 45 percent. Thus, the prophylaxis may be efficient, but its clinical use is limited to patient populations with a high incidence of VTE. Further studies to identify medical patients who are at high risk and would benefit from prophylaxis are warranted.}}, author = {{Själander, Anders and Jansson, Jan-Åke and Bergqvist, David and Eriksson, Henry and Svensson, Peter}}, issn = {{0023-7205}}, keywords = {{Fibrinolytika; Ventrombos; Blodförtunningsmedel; Blodproppssjukdomar}}, language = {{swe}}, number = {{20-21}}, pages = {{1585--1587}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Evidens för trombosprofylax till medicinpatienter med hög risk}}, url = {{http://ltarkiv.lakartidningen.se/artNo33449}}, volume = {{104}}, year = {{2007}}, }